Wegovy for Weight Loss: Clinical Results & What to Expect

What Is Wegovy?

Wegovy is the obesity-specific formulation of semaglutide, manufactured by Novo Nordisk. It contains 2.4 mg of semaglutide per weekly dose — the highest dose of any approved semaglutide product.

Wegovy received FDA approval in June 2021 for:

• Chronic weight management in adults with BMI ≥30 (obesity), or
• BMI ≥27 (overweight) plus at least one weight-related condition (hypertension, type 2 diabetes, sleep apnea, cardiovascular disease, or dyslipidemia)

It's intended as a long-term treatment alongside dietary changes and physical activity, not a short-term course.

Wegovy Weight Loss Results: The Evidence

Five major STEP trials established Wegovy's clinical profile:

STEP 1 (primary obesity trial, n=1,961):

• 14.9% average weight loss at 68 weeks
• 86% lost ≥5% of starting weight
• 50% lost ≥15% of starting weight
• Placebo group lost 2.4% (confirms it's the medication doing the work)

STEP 3 (with intensive lifestyle counseling):

• 16.0% average weight loss — behavior plus medication produces better results than either alone

STEP 5 (2-year data):

• 15.2% maintained at 104 weeks — durable weight loss with continued treatment

SELECT (cardiovascular outcomes, 2023):

• 20% reduction in cardiovascular events (heart attack, stroke, CV death) in people with obesity and established heart disease
• Wegovy added a cardiovascular indication in 2024 — now approved as the first weight loss drug to reduce CV risk

What Wegovy Feels Like: The Patient Experience

Weeks 1–4 (0.25 mg): Most patients describe modest appetite change and possibly nausea. Weight loss is typically 2–5 lbs.

Months 2–4 (0.5 mg to 1 mg): Appetite suppression becomes more pronounced. Nausea often peaks then begins declining. Weight loss accelerates.

Months 4–6 (1.7 mg to 2.4 mg): Full dose reached. Most patients describe this as the period of fastest weight loss — 1–2 lbs per week is common.

Months 6–18: Weight loss continues but slows. Plateau is reached for most patients between months 12–18.

The experience most consistently described: food "doesn't call to you" the way it used to. Smaller portions feel satisfying. The constant mental preoccupation with food diminishes.

Wegovy Side Effects

Common (affecting >10%):

• Nausea — 44% of Wegovy patients; typically worst in weeks 2–12, then diminishes
• Diarrhea — 30%
• Vomiting — 24%
• Constipation — 24%
• Abdominal pain — 20%

Most GI side effects improve substantially after the first 3 months as the gut adapts to slower gastric emptying.

Serious (rare):

• Acute pancreatitis
• Gallbladder disease (cholelithiasis)
• Acute kidney injury (usually from dehydration with severe vomiting)

Black box warning: Thyroid C-cell tumors in rodents; contraindicated in personal or family history of medullary thyroid carcinoma or MEN2.

Wegovy Cost and Insurance

List price: ~$1,350/month (2025)

Savings programs:

• NovoCare Savings Card: as low as $25/month for eligible commercially insured patients
• Patient assistance programs for qualifying low-income patients

Insurance coverage: Improved significantly since 2021 but still inconsistent. Medicare Part D covers Wegovy as of 2024. Many commercial plans require prior authorization with documentation of obesity and failed lifestyle interventions.

Bottom Line

Wegovy is the gold standard GLP-1 medication for obesity — the most clinically studied, the one with cardiovascular outcome data, and the one with the full FDA obesity indication at the optimal dose. Its main drawbacks are cost and supply variability. For most qualifying patients, it produces transformative, durable results.

Sources

• Wilding JPH et al., "Once-Weekly Semaglutide in Adults with Overweight or Obesity," NEJM, 2021
• Ryan DH et al., "Long-term weight loss effects of semaglutide in obesity without diabetes," The Lancet, 2021
• Lincoff AM et al., "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes," NEJM, 2023